Sepsis

Sepsis is a life-threatening condition resulting from uncontrolled severe infections, which affects an estimated three million people a year worldwide. Few industry pipelines are focused on the development of products specifically for registration for the treatment of sepsis or septic shock.

OUR FOCUS

In the pipeline

The development programme for CytoFab^™, our potential treatment for severe sepsis licensed from Protherics, continues in Phase II development. CytoFab^™ has the potential to be one of a limited number of medicines specifically developed for such patients.